Table 1.
Healthy People 2020 CKD objectives
| Goal No. | Stated Goal | Improvement Sought, % |
| CKD-1 | Reduce the proportion of the United States population with CKD | 10 |
| CKD-2 | Increase the proportion of persons with CKD who know that they have impaired renal function | 4 |
| CKD-3 | Increase the proportion of hospital patients who incurred AKI who have follow-up renal evaluation in 6 mo postdischarge | 10 |
| CKD-4.1 | Increase the proportion of persons with CKD who receive medical evaluation with serum creatinine, lipids, and microalbuminuria | 10 |
| CKD-4.2 | Increase the proportion of persons with type 1 or 2 diabetes and CKD who receive medical evaluation with serum creatinine, microalbuminuria, A1c, lipids, and eye examinations | 10 |
| CKD-5 | Increase the proportion of persons with diabetes and CKD who receive recommended medical treatment with ACEIs or ARBs | 10 |
| CKD-6.1 | Reduce the proportion of persons with CKD who have elevated BP | Minimal statistical significancea |
| CKD-6.2 | Increase the proportion of adults ages ≥50 yr old with CKD who currently take statins to lower their blood cholesterol | Minimal statistical significancea |
| CKD-7 | Reduce the number of deaths among persons with CKD | Tracked for informational purposesa |
| CKD-8 | Reduce the number of new patients with ESRD | 10 |
| CKD-9.1b | Reduce kidney failure caused by diabetes | 10 |
| CKD-9.2 | Reduce kidney failure caused by diabetes among persons with diabetes | 10 |
| CKD-10b | Increase the proportion of patients with CKD receiving care from a nephrologist at least 12 mo before the start of RRT | 10 |
| CKD-11.1 | Increase the proportion of adult patients on HD who use AVFs as the primary mode of vascular access | 10 |
| CKD-11.2 | Reduce the proportion of adult patients on HD who use catheters as the only mode of vascular access | 10 |
| CKD-11.3b | Increase the proportion of adult patients on HD who use AVFs or have maturing AVFs as the primary mode of vascular access at the start of RRT | 10 |
| CKD-12 | Increase the proportion of patients on dialysis waitlisted and/or receiving a deceased donor KT within 1 yr of ESRD start (among patients <70 yr of age) | 10 |
| CKD-13.1 | Increase the proportion of patients receiving a KT within 3 yr of ESRD | 10 |
| CKD-13.2 | Increase the proportion of patients who receive a preemptive KT at the start of ESRD | Tracked for informational purposesa |
| CKD-14.1b | Reduce the total number of deaths for persons on dialysis | 10 |
| CKD-14.2b | Reduce the number of deaths in patients on dialysis within the first 3 mo of initiation of RRT | 10 |
| CKD-14.3b | Reduce the number of cardiovascular deaths for persons on dialysis | 10 |
| CKD-14.4 | Reduce the total number of deaths for persons with a functioning KT | 10 |
| CKD-14.5 | Reduce the number of cardiovascular deaths in persons with a functioning KT | 2 |
ACEI, angiotensin–converting enzyme inhibitor; ARB, angiotensin receptor blocker; HD, hemodialysis; AVF, arteriovenous fistula; KT, kidney transplant. Modified from the US Department of Health and Human Services’ Healthy People 2020: Chronic Kidney Disease (24), with permission.
a
Details and contextualization are in the US Department of Health and Human Services’ Healthy People 2020: Chronic Kidney Disease (24).
b
Goals that were addressed in this study.